Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Djordje Atanackovic, Mary Steinbach, Sabarinath Venniyil Radhakrishnan & Tim Luetkens. (2016) Immunotherapies targeting CD38 in Multiple Myeloma. OncoImmunology 5:11.
Read now
Read now
Kylie D. Mason & Surender Juneja. (2008) Go with the flow for monitoring response in myeloma with minimal residual disease. Leukemia & Lymphoma 49:2, pages 177-178.
Read now
Read now
Articles from other publishers (19)
Hongwen Li, Jing Li, Jiazhuo Wu, Zhuangzhuang Shi, Yuyang Gao, Wenting Song, Jiwei Li, Zhaoming Li & Mingzhi Zhang. (2023)
A second‐generation
CD38‐CAR‐T
cell for the treatment of multiple myeloma
. Cancer Medicine 12:9, pages 10804-10815.
Crossref
Crossref
Michael Olson, Sabarinath Venniyil Radhakrishnan, Tim Luetkens & Djordje Atanackovic. (2019) The role of surface molecule CD229 in Multiple Myeloma. Clinical Immunology 204, pages 69-73.
Crossref
Crossref
Hanqing Li, Feng Li, Xiaogang Zhou, Jiangang Mei, Ping Song, Zhiming An, Qian Zhao, Xing Guo, Xuli Wang & Yongping Zhai. (2019) Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis. Annals of Hematology 98:5, pages 1185-1195.
Crossref
Crossref
Fanny Pojero, Alessandra Casuccio, Maria Francesca Parrino, Giovanni Cardinale, Giuseppina Colonna Romano, Calogero Caruso & Francesco Gervasi. (2015) Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual plasma cell analysis. Cytometry Part B: Clinical Cytometry 88:3, pages 165-182.
Crossref
Crossref
Prashant R. Tembhare, Constance M. Yuan, David Venzon, Raul Braylan, Neha Korde, Elisabet Manasanch, Diamond Zuchlinsky, Katherine Calvo, Roger Kurlander, Manisha Bhutani, Nishant Tageja, Irina Maric, Marcia Mulquin, Mark Roschewski, Mary Kwok, David Liewehr, Ola Landgren & Maryalice Stetler-Stevenson. (2014) Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research 38:3, pages 371-376.
Crossref
Crossref
Mark Korthals, Nina Sehnke, Ralf Kronenwett, Thomas Schroeder, Tobias Strapatsas, Guido Kobbe, Rainer Haas & Roland Fenk. (2013) Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation 19:7, pages 1109-1115.
Crossref
Crossref
Suzane Dal Bó, Annelise Pezzi, Bruna Amorin, Vanessa Valim, Rosane Isabel Bittencourt & Lucia Silla. (2013) Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation. ISRN Hematology 2013, pages 1-7.
Crossref
Crossref
Matthew C. Cheung & Kevin R. Imrie. 2013. Patient Surveillance After Cancer Treatment. Patient Surveillance After Cancer Treatment
503
509
.
Andrew J. Hart, Madan H. Jagasia, Annette S. Kim, Claudio A. Mosse, Bipin N. Savani & Adetola Kassim. (2012) Minimal Residual Disease in Myeloma: Are We There Yet?. Biology of Blood and Marrow Transplantation 18:12, pages 1790-1799.
Crossref
Crossref
Elisa Cannizzo, Giovanni Carulli, Luigi Del Vecchio, Virginia Ottaviano, Emanuele Bellio, Ezio Zenari, Antonio Azzarà, Mario Petrini & Frederic Preffer. (2012) The Role of CD19 and CD27 in the Diagnosis of Multiple Myeloma by Flow Cytometry. American Journal of Clinical Pathology 137:3, pages 377-386.
Crossref
Crossref
Fu-Jun Hu, Ming-Hua Ge, Pei Li, Chang-Chun Wang, Yu-Tian Ling, Wei-Min Mao & Zhi-Qiang Ling. (2012) Unfavorable clinical implications of circulating CD44+ lymphocytes in patients with nasopharyngeal carcinoma undergoing radiochemotherapy. Clinica Chimica Acta 413:1-2, pages 213-218.
Crossref
Crossref
Carlos Fernández de Larrea, Natalia Tovar, María Rozman, Laura Rosiñol, Juan Ignacio Aróstegui, María Teresa Cibeira, Montserrat Rovira, Jordi Yagüe & Joan Bladé. (2011) Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional Morphology on Disease Progression. Biology of Blood and Marrow Transplantation 17:7, pages 1084-1087.
Crossref
Crossref
Bruno PaivaJoaquin Martinez-LopezMaria-Belen VidrialesMaria-Victoria MateosMaria-Angeles MontalbanElena Fernandez-RedondoLourdes AlonsoAlbert OriolAna-Isabel TeruelRaquel de PazJosé-Garcia LarañaEnrique BengoecheaAlejandro MartinJoaquin Diaz MediavillaLuis PalomeraFelipe de ArribaJoan BladéAlberto OrfaoJuan-Jose LahuertaJesus F. San Miguel. (2011) Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. Journal of Clinical Oncology 29:12, pages 1627-1633.
Crossref
Crossref
Constance M. Yuan & Maryalice Stetler-Stevenson. (2011) Role of Flow Cytometry of Peripheral Blood and Bone Marrow Aspirates in Early Myeloma. Seminars in Hematology 48:1, pages 32-38.
Crossref
Crossref
Elisa Cannizzo, Emanuele Bellio, Aliyah R. Sohani, Robert P. Hasserjian, Judith A. Ferry, Michelle E. Dorn, Craig Sadowski, Janessa J. Bucci, Giovanni Carulli & Frederic Preffer. (2010) Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry Part B: Clinical Cytometry 78B:4, pages 231-238.
Crossref
Crossref
Bruno Paiva, Julia Almeida, Martin Pérez‐Andrés, Gema Mateo, Antonio López, Ana Rasillo, María‐Belén Vídriales, María‐Consuelo López‐Berges, Jesús F. San Miguel & Alberto Orfao. (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders. Cytometry Part B: Clinical Cytometry 78B:4, pages 239-252.
Crossref
Crossref
B. Paiva, M.-B. Vidriales, G. Mateo, J. J. Perez, M. A. Montalban, A. Sureda, L. Montejano, N. C. Gutierrez, A. Garcia de Coca, N. de las Heras, M. V. Mateos, M. C. Lopez-Berges, R. Garcia-Boyero, J. Galende, J. Hernandez, L. Palomera, D. Carrera, R. Martinez, J. de la Rubia, A. Martin, Y. Gonzalez, J. Blade, J. J. Lahuerta, A. Orfao & J. F. San-Miguel. (2009) The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 114:20, pages 4369-4372.
Crossref
Crossref
Bruno PaivaMaria-Belén VidrialesJorge CerveróGema MateoJose J. PérezMaria A. MontalbánAnna SuredaLaura MontejanoNorma C. GutiérrezAlfonso García de CocaNatalia de las HerasMaria V. MateosMaria C. López-BergesRaimundo García-BoyeroJosefina GalendeJose HernándezLuis PalomeraDolores CarreraRafael MartínezJavier de la RubiaAlejandro MartínJoan Bladé, Juan J. LahuertaAlberto Orfao & Jesús F. San Miguel. (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:10, pages 4017-4023.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Crossref